Tabelecleucel
- Generic Name
- Tabelecleucel
- Brand Names
- Ebvallo
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- G3NJ7M8N4H
- Background
Tabelecleucel is an innovative therapy that uses Epstein-Barr virus (EBV)-specific allogeneic cytotoxic T cells (CTLs). It is produced by mixing T-cells with B-cells that have been infected with the Epstein-Barr virus (EBV). Both T-cells and B-cells are obtained from the same donor, and T-cells are grown to increase their numbers. When given to a patient wit...
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Evaluate Tabelecleucel in Participants with Epstein-barr Virus-associated Diseases
- Conditions
- Epstein-Barr Virus (EBV)-associated DiseasesEBV+ Lymphoproliferative Disease with Primary Immunodeficiency (EBV+ PID LPD)EBV+ Lymphoproliferative Disease with Acquired (non-congenital) Immunodeficiency (EBV+ AID LPD)EBV+ Posttransplant Lymphoproliferative Disease in Central Nervous System (EBV+ CNS PTLD)EBV+ Post-transplant Lymphoproliferative Disease (EBV+ PTLD)Solid Organ Transplant ComplicationsLymphoproliferative DisordersAllogeneic Hematopoietic Cell TransplantStem Cell Transplant ComplicationsEBV+ Sarcomas
- Interventions
- First Posted Date
- 2020-09-18
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Atara Biotherapeutics
- Target Recruit Count
- 190
- Registration Number
- NCT04554914
- Locations
- 🇺🇸
University of California Los Angeles (UCLA) (Adults and Pediatrics), LOS Angeles, California, United States
🇺🇸Children's Hospital of Orange County (Pediatrics [up to 25 years old]), Orange, California, United States
🇺🇸Lucile Packard Children's Hospital Stanford (Pediatrics only), Palo Alto, California, United States
Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)
- First Posted Date
- 2018-12-07
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Atara Biotherapeutics
- Target Recruit Count
- 12
- Registration Number
- NCT03769467
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Stanford Hospital and Clinics, Palo Alto, California, United States
Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy
- First Posted Date
- 2018-01-09
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Atara Biotherapeutics
- Target Recruit Count
- 66
- Registration Number
- NCT03394365
- Locations
- 🇺🇸
University of Maryland School of Medicine (Adults only), Baltimore, Maryland, United States
🇺🇸Arthur M. Blank Hospital (Pediatrics), Atlanta, Georgia, United States
🇺🇸City of Hope (Adults and Pediatrics), Duarte, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.